roe.co glp 1 Ro Launches Wegovy® Pill Through Integration with Novo Nordisk Ro launches GLP-1 supply tracker

[DOI] [PMC free article] [PubMed] [Google Scholar] 135.Ye X., Zhou Q., Ren P., Xiang W., Xiao L

BPC-157s tissue-protective properties may help counteract the increased injury risk that comes with training on ice, snow, and frozen terrain

That includes 11% that report using them specifically for weight loss as well as 11% who use GLP-1s to treat diabetes

You meet the FDA threshold without needing comorbidities

In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it